JP7514840B2 - カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 - Google Patents

カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 Download PDF

Info

Publication number
JP7514840B2
JP7514840B2 JP2021538171A JP2021538171A JP7514840B2 JP 7514840 B2 JP7514840 B2 JP 7514840B2 JP 2021538171 A JP2021538171 A JP 2021538171A JP 2021538171 A JP2021538171 A JP 2021538171A JP 7514840 B2 JP7514840 B2 JP 7514840B2
Authority
JP
Japan
Prior art keywords
dry powder
pharmaceutical composition
csp7
powder pharmaceutical
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021538171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500500A5 (https=
JPWO2020055824A5 (https=
JP2022500500A (ja
Inventor
ロバート オー． ザ サード ウィリアムズ，
アラン ビー． ワッツ，
ヤジエ ジャン，
サウィトリー サハキジピジャルン，
デール クリステンセン，
ジョン ジェイ． コレング，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2022500500A publication Critical patent/JP2022500500A/ja
Publication of JP2022500500A5 publication Critical patent/JP2022500500A5/ja
Publication of JPWO2020055824A5 publication Critical patent/JPWO2020055824A5/ja
Priority to JP2024106451A priority Critical patent/JP2024114982A/ja
Application granted granted Critical
Publication of JP7514840B2 publication Critical patent/JP7514840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2021538171A 2018-09-10 2019-09-10 カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 Active JP7514840B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024106451A JP2024114982A (ja) 2018-09-10 2024-07-01 カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729010P 2018-09-10 2018-09-10
US62/729,010 2018-09-10
PCT/US2019/050349 WO2020055824A1 (en) 2018-09-10 2019-09-10 Dry powder formulation of caveolin-1 peptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024106451A Division JP2024114982A (ja) 2018-09-10 2024-07-01 カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法

Publications (4)

Publication Number Publication Date
JP2022500500A JP2022500500A (ja) 2022-01-04
JP2022500500A5 JP2022500500A5 (https=) 2022-09-09
JPWO2020055824A5 JPWO2020055824A5 (https=) 2022-09-09
JP7514840B2 true JP7514840B2 (ja) 2024-07-11

Family

ID=69778150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538171A Active JP7514840B2 (ja) 2018-09-10 2019-09-10 カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法
JP2024106451A Pending JP2024114982A (ja) 2018-09-10 2024-07-01 カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024106451A Pending JP2024114982A (ja) 2018-09-10 2024-07-01 カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法

Country Status (9)

Country Link
US (3) US12280088B2 (https=)
EP (1) EP3849581A4 (https=)
JP (2) JP7514840B2 (https=)
KR (1) KR20210057127A (https=)
CN (2) CN112996530B (https=)
AU (1) AU2019339264B2 (https=)
BR (1) BR112021004420A2 (https=)
CA (1) CA3109982A1 (https=)
WO (1) WO2020055824A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110201144B (zh) 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
US20240082342A1 (en) * 2018-11-21 2024-03-14 Board Of Regents, The University Of Texas System Peptide therapeutics for increasing lung cell viability
US20220370544A1 (en) * 2018-11-21 2022-11-24 Board Of Regents, The University Of Texas System Peptide therapeutics for acute and chronic airway and alveolar diseases
WO2020185826A1 (en) * 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
EP4138791A1 (en) * 2020-04-20 2023-03-01 Board of Regents, The University of Texas System Biologically active dry powder compositions and method of their manufacture and use
US20230159608A1 (en) * 2020-04-21 2023-05-25 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and uses thereof
US20230226149A1 (en) * 2020-06-19 2023-07-20 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
US20250041383A1 (en) * 2021-06-17 2025-02-06 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of post-acute covid-19
US20250262273A1 (en) * 2021-10-22 2025-08-21 Rein Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of chronic kidney disease
EP4719450A2 (en) * 2023-05-30 2026-04-08 Rein Therapeutics, Inc. Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof
CN121695995A (zh) * 2024-09-18 2026-03-20 深圳翰宇药业股份有限公司 一种多肽药物的粉碎方法
CN119661656A (zh) * 2024-11-20 2025-03-21 华中科技大学同济医学院附属梨园医院 一种靶向拮抗pCAV1的多肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503321A (ja) 2000-09-08 2005-02-03 イエール・ユニバーシテイ カベオリンペプチド及び治療薬としてのそれらの使用
JP2018507867A (ja) 2015-02-27 2018-03-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ポリペプチド治療及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
EP1501479A1 (en) 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
EP2074142A4 (en) * 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
EP2635686B1 (en) 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
BR112015022831A2 (pt) 2013-03-13 2017-08-22 Forest Laboratories Holdings Ltd Composições farmacêuticas micronizadas
CN110201144B (zh) * 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
WO2015080980A2 (en) 2013-11-26 2015-06-04 E&B Technologies Llc Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
EP3262856B1 (en) * 2015-02-27 2020-02-19 PCMS Holdings, Inc. Systems and methods for secure roll-over of device ownership

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503321A (ja) 2000-09-08 2005-02-03 イエール・ユニバーシテイ カベオリンペプチド及び治療薬としてのそれらの使用
JP2018507867A (ja) 2015-02-27 2018-03-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ポリペプチド治療及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Caveolin-1 scaffolding domain peptide，Enzo，2018年08月28日，https://web.archive.org/web/20180828064451/https://www.enzolifesciences.com/ALX-153-064/caveolin-1-scaffolding-domain-peptide/
Cell. Mol. Neurobiol.，2011年，vol.31, issue 7，p.991-997
Drug Delivery System，2006年，vol.21, no.4，p.417-425

Also Published As

Publication number Publication date
AU2019339264B2 (en) 2025-05-29
CN112996530B (zh) 2025-06-03
US20210260150A1 (en) 2021-08-26
JP2024114982A (ja) 2024-08-23
WO2020055824A1 (en) 2020-03-19
CA3109982A1 (en) 2020-03-19
US20240269225A1 (en) 2024-08-15
CN120459067A (zh) 2025-08-12
AU2019339264A1 (en) 2021-03-11
BR112021004420A2 (pt) 2021-06-01
CN112996530A (zh) 2021-06-18
US20250302910A1 (en) 2025-10-02
US12280088B2 (en) 2025-04-22
EP3849581A1 (en) 2021-07-21
WO2020055824A8 (en) 2020-05-14
EP3849581A4 (en) 2022-07-06
JP2022500500A (ja) 2022-01-04
KR20210057127A (ko) 2021-05-20
US12280089B2 (en) 2025-04-22

Similar Documents

Publication Publication Date Title
JP7514840B2 (ja) カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法
JP7737492B2 (ja) Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
WO2021257816A2 (en) Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
US20250041383A1 (en) Modified caveolin-1 peptides for the treatment of post-acute covid-19
US20250262273A1 (en) Modified caveolin-1 peptides for the treatment of chronic kidney disease
EP3937966A1 (en) Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
KR102958241B1 (ko) Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240701

R150 Certificate of patent or registration of utility model

Ref document number: 7514840

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350